Brief: Double Bond Pharmaceutical Receives Patent In U.S. For BeloGal Platform
31/07/2018 07:16
July 31 (Reuters) - Double Bond Pharmaceutical International
AB (publ) DBPHAb.TE "
* DOUBLE BOND PHARMACEUTICAL RECEIVES PATENT IN THE UNITED
STATES
FOR THE BELOGAL® PLATFORM
* PATENT APPROVAL PROVIDES PROTECTION FOR TECHNOLOGY
PLATFORM
BELOGAL® AND PRODUCTS ON US MARKET AT LEAST THROUGH 2035
Source text for Eikon: ID:nWkrbgpzyH
Further company coverage: DBPHAb.TE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Double Bond Pharmaceutical International AB (publ)
See all newsBrief: DBP International AB And Vivo Biopharma LLC Revised Asset Purchase And Collaboration Agreements
Brief: DBP International AB And Vivo Biopharma LLC Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: DBP And Vivo Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: Double Bond Pharmaceutical Says Positive Response For SI-053 From Ethical Committee In Netherlands Has Been Received
Brief: Double Bond To Cooperate With Belarus State Medical University